Kennedy Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Kennedy Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.22M	Sell	36,775 -2,359	-6%	-$407K	0.13%	243
2025 Q4	$7.15M	Buy	39,134 +360	+0.9%	+$50.3K	0.15%	219
2025 Q3	$4.71M	Buy	38,774 +10,819	+39%	+$1.22M	0.1%	307
2025 Q2	$2.92M	Buy	27,955 +22,133	+380%	+$2.34M	0.07%	380
2025 Q1	$679K	Sell	5,822 -32,119	-85%	-$3.66M	0.02%	558
2024 Q4	$3.21M	Buy	37,941 +18,510	+95%	+$1.7M	0.07%	413
2024 Q3	$1.75M	Sell	19,431 -1,184	-6%	-$103K	0.04%	535
2024 Q2	$1.66M	Buy	20,615 +1,132	+6%	+$83.8K	0.04%	533
2024 Q1	$1.55M	Buy	19,483 +6,136	+46%	+$515K	0.03%	563
2023 Q4	$1.06M	Buy	13,347 +1,255	+10%	+$83.9K	0.02%	580
2023 Q3	$845K	Buy	12,092 +2,354	+24%	+$176K	0.02%	580
2023 Q2	$700K	Buy	+9,738	New	+$718K	0.02%	580

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kennedy Capital Management's AXSM Position: Q1 2026 in Review

Kennedy Capital Management reduced its Axsome Therapeutics (AXSM) stake by 6% in Q1 2026, selling an estimated $407K and leaving 36,775 shares worth $6.22M. The position accounts for 0.13% of the portfolio, ranked #243.

Kennedy Capital Management first reported a position in AXSM in Q2 2023 and has held it in 12 quarters since. The position peaked at $7.15M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Kennedy Capital Management held 36,775 shares of Axsome Therapeutics worth $6.22M as of Q1 2026.
Kennedy Capital Management sold 2,359 Axsome Therapeutics shares in Q1 2026, an estimated $407K.
Axsome Therapeutics made up 0.13% of Kennedy Capital Management's portfolio in Q1 2026, its #243 holding.
Kennedy Capital Management first reported a position in Axsome Therapeutics in Q2 2023 and has held it in 12 quarters since.
Kennedy Capital Management's Axsome Therapeutics position peaked at $7.15M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Kennedy Capital Management's 13F filing for Q1 2026, filed 13 May 2026.